Results 21 to 30 of about 15,817 (194)

“Black box warning” rash with entecavir - case report

BMC Gastroenterology, 2020
Background Hepatitis B infection is a significant worldwide health issue, predispose to the development of liver cirrhosis and hepatocellular carcinoma.
Xiong Khee Cheong, Zhiqin Wong, Norazirah Md Nor, Bang Rom Lee   +3 more
doaj   +1 more source

Impact of HBcrAg levels on HBsAg seroconversion after HBV rebound: a case report

Journal of Pharmaceutical Health Care and Sciences, 2023
Background Nucleoside analogues (NAs) such as entecavir are required for at least 12 months when patients with resolved hepatitis B virus (HBV) infection develop HBV reactivation.
Maki Ohkubo, Kuniaki Fukuda, Shigeru Chiba, Masato Homma   +3 more
doaj   +1 more source

Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease [PDF]

, 2015
Hepatitis B virus (HBV) infection is a dynamic state of interactions among HBV, hepatocytes, and the host immune system. Natural history studies of chronic hepatitis B (CHB) infection have shown an association between active viral replication and adverse
Farinati, Fabio, Gottardo, G, Rodr\uedguez Castro, K, Russo, FRANCESCO PAOLO, Scribano, L, Vanin, V   +5 more
core   +1 more source

Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-Naïve chronic HBV patients [PDF]

, 2013
Background: Immunomodulators and Nucleotide analogues have been used globally for the dealing of chronic hepatitis B virus (HBV) infection. However, the development of drug resistance is a major limitation to their long-term effectiveness.
Abedi, F., Alavian, S.M., Ataei, B., Azad, T.M., Daram, M., Fazeli, Z., Ghamari, S., Goodarzi, Z., Jazayeri, S.M., Judaki, M.A., Kalantari, E., Karimzadeh, H., Keyvani, H., Khedive, A., Mahabadi, M., Mahmoodi, M., Malekzadeh, R., Mansour-Ghanaei, F., Montazeri, G., Moradi, A., Nejatizadeh, A., Norouzi, M., Pourhosseingholi, M.A., Rafatpanah, H., Ramezani, F., Saberfar, E., Saberfiroozi, M., Samimirad, K., Sanei-Moghaddam, I., Sarizadeh, G., Sayad, B., Somi, M.H., Yaran, M., Ziee, M.   +33 more
core   +1 more source

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries

Journal of Virus Eradication, 2015
Background: In 2013, an estimated 686,000 people died from hepatitis B virus (HBV) infection worldwide. Mass treatment programmes for hepatitis B will require very low drug costs.
Andrew Hill, Dzintars Gotham, Graham Cooke, Sanjay Bhagani, Isabelle Andrieux-Meyer, Jennifer Cohn, Joseph Fortunak   +6 more
doaj   +1 more source

A cost utility and cost effectiveness analysis of different oral antiviral medications in patients with HBeAg-Negative chronic hepatitis B in Iran: an economic microsimulation decision model [PDF]

, 2016
Background: Although hepatitis B infection is the major cause of chronic liver disease in Iran, no studies have employed economic evaluations of the medications used to treat Iranian patients with chronic hepatitis B (CHB).
Alavian, Seyed Moayed, Javanbakht, Mehdi, Kebriaeezadeh, Abbas, Keshavarz, Khosro, Keshvari, Maryam, Lotfi, Farhad, Meshkini, Amir Hashemi, Nikfar, Shekoufeh, Rezaei Hemami, Mohsen, Sari, Ali Akbari   +9 more
core   +1 more source

The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis

Gastroenterology Research and Practice, 2016
Background. Currently, both of entecavir and lamivudine are effective for patients with HBV-associated acute-on-chronic liver failure (ACLF). However, there is no consensus on the efficacy of entecavir versus lamivudine for patients with HBV-associated ...
Jiao Yang, Hang Sun, Qi Liu
doaj   +1 more source

Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery: A network meta-analysis

Frontiers in Oncology, 2023
ObjectiveIn this study, we aimed to perform a network meta-analysis to compare the effectiveness of NAs in decreasing the reactivation of HBV, reducing chemotherapy disruption, and improving survival in oncology patients.MethodsRelevant randomized ...
Yuqing Zhao, Yuqing Zhao, Yingying Song, Huan Zhang, Huan Zhang, Tongshuo Qu, Tongshuo Qu, Malina Axinbai, Malina Axinbai, Yidian Yang, Yidian Yang, Liping Zhang, Liping Zhang   +12 more
doaj   +1 more source

Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis

The Saudi Journal of Gastroenterology, 2015
Background/Aim: Hepatic steatosis may influence the response to antivirals in chronic hepatitis B patients. This study aimed to compare the efficacy of entecavir and tenofovir in nucleos(t) ide-naive chronic hepatitis B patients with hepatosteatosis ...
Zeynal Dogan, Levent Filik, Bilal Ergül, Murat Sarikaya   +3 more
doaj   +1 more source

Liver transplantation for viral hepatitis in 2015 [PDF]

, 2016
Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Nadal, Elena, Russo, FRANCESCO PAOLO, Senzolo, Marco, Zanetto, Alberto   +8 more
core   +1 more source